Articles from Calibr-Skaggs Institute for Innovative Medicines

The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development arm of Scripps Research, today announced two milestones in the clinical advancement of CLF065, its potential best-in-class, long-acting glucagon-like peptide-2 (GLP-2) receptor agonist in development for inflammatory bowel diseases (IBD). Calibr-Skaggs has enrolled the first patient in its Phase 2 study of CLF065 in chronic pouchitis and has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a Phase 2, 105-patient study in Crohn’s disease. Interest in next-generation GLP-2 analogs has accelerated with active programs from Ironwood, Zealand, and recently Lilly/Hanmi targeting short bowel syndrome. CLF065 is the first long-acting GLP-2 analog to enter Phase 2 trials specifically for IBD, with a pharmacology that supports the potential for once-monthly dosing intervals.